Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels*
References (26)
- et al.
Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction
J Am Coll Cardiol
(2000) - et al.
Increased local temperature in human coronary atherosclerotic plaques: An independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention
J Am Coll Cardiol
(2001) - et al.
Activated coagulation/ fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels
Thromb Res
(2000) - et al.
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Blood
(1993) - et al.
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy
J Am Coll Cardiol
(2000) - et al.
The adhesion molecule P-selectin and cardiovascular disease
Eur Heart J
(2003) - et al.
Increased soluble form of P-selectin in patients with unstable angina
Circulation
(1995) 2004 Heart and Stroke Statistical Update
- et al.
Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients. An in vivo intravascular ultrasound study
Eur Heart J
(1997) - et al.
Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62)
J Immunol
(1993)
Inflammation and thrombosis: The clot thickens
Circulation
Independent prognostic value of elevated C-reactive protein in unstable angina
Circulation
Soluble CD40 ligand in acute coronary syndromes
N Engl J Med
Cited by (29)
High Serum sCD40L Levels During the First Week of Malignant Middle Cerebral Artery Infarction and Mortality
2019, World NeurosurgeryCitation Excerpt :We have excluded patients with diseases that could affect serum sCD40L levels such as sepsis,40 traumatic brain injury,41 and liver diseases,42 and also patients taking statins, for the same reason.28-30 Antiplatelet agents could also affect serum sCD40L levels43-49; however, we have not found significant differences in the antiplatelet treatment rate between survivor and nonsurvivor patients. An association has been found between some genetic polymorphisms and serum sCD40L levels50-54; however, we have not explored genetic polymorphisms and thus, it is possible that genetics could contribute to the difference in serum sCD40L levels between survivor and nonsurvivor patients.
Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers
2018, Journal of Vascular SurgeryCitation Excerpt :Dual antiplatelet therapy consisting of aspirin and clopidogrel in recently symptomatic patients expecting CEA has been associated with a significant reduction in recurrent neurologic events and spontaneous embolization before CEA without significant increase in major perioperative bleeding.28 Another trial analyzing acute coronary syndrome patients showed significant reduction in platelet-released inflammatory mediators in patients with high baseline hs-CRP concentration who were treated with clopidogrel in addition to aspirin.29 In addition to aspirin and clopidogrel, statins might have a crucial role in the prevention of exacerbated inflammatory response, mostly because of their pleiotropic effects.31,32
From Atherosclerosis to Acute Coronary Syndromes: The Role of Soluble CD40 Ligand
2010, Trends in Cardiovascular MedicineCitation Excerpt :In patients with stable CAD, clopidogrel inhibited the release of sCD40L by platelets, measured at baseline and at 8 weeks (Azar et al. 2006). Moreover, concerning the effects of dual antiplatelet therapy, patients with high levels of high-sensitivity C-reactive protein (CRP) and sCD40L, receiving both acetylsalicylic acid and clopidogrel, exhibited a significantly lower prevalence of major cardiovascular events compared with that in the acetylsalicylic acid group (Vavuranakis et al. 2006). Ticagrelor, similarly with clopidogrel, inhibits platelet function by inhibiting the P2Y12 ADP receptor.
The role of platelets CD40 ligand (CD154) in acute coronary syndromes
2009, Thrombosis ResearchCitation Excerpt :On the other hand, the present study found a significant positive correlation between indicators of platelet CD154 (percentage and GMFI) and their congeners of P-selectin among patients with CAD. Our results were in agreement with other previous reports [19,28] and confirmed by logistic regression analyses. Ox-LDL is a more potent pro-atherosclerotic mediator than the native unmodified LDL.
Platelet activation in coronary artery disease: Intracardiac vs peripheral venous levels and the effects of angioplasty
2007, ChestCitation Excerpt :Indeed, the lower MPC levels after PCI may again reflect our aggressive antiplatelet therapy regime, although we noted morphologic changes within the platelets (larger and more granular) that were suggestive of some activation following PCI. In this study, PCI induced a significant reduction in soluble CD40L levels from both intracardiac and extracardiac samples to a similar degree, which is in contrast to the results of other studies4243 The main difference between our study and previous work was the aggressive use of antiplatelet drugs (which may “damp down” the CD40L response44) and the timing of the sampling. Nonetheless, differences in procedural variables (eg, stenting deployment without prior balloon predilatation or high-pressure stent deployment for a shorter duration) may underline some of the differing-term platelet responses.
- *
This article was presented in poster form at the American College of Cardiology Annual Scientific Session 2005, Orlando, Florida, March 6–9, 2005.